Clinical Trial Trends: Non-malignant Hematology

Non-malignant hematology refers to classical hematology conditions, encompassing a diverse range of diseases affecting the blood and its components without involving cancerous growths. These disorders can impact red blood cells, white blood cells, platelets, or plasma proteins, leading to various health challenges. Unlike hematologic malignancies such as leukemia or lymphoma, non-malignant blood disorders do not involve uncontrolled proliferation of abnormal cells but can still significantly affect an individual’s health and quality of life.

Common non-malignant hematologic disorders include anemia, clotting disorders like hemophilia, and platelet function disorders. These conditions often require specialized management to prevent complications and improve patient outcomes—and they vary wildly in incidence and prognosis. Globally, 40% of children under the age of 5 and 30% of women aged 15-49 are impacted by anemia. In contrast, the incidence rate for thrombotic thrombocytopenic purpura is just 4-11 patients in one million per year. In addition, non-malignant hematologic disorders may be genetic, immune-mediated, or caused by infection.

Advancements in diagnostic techniques and therapeutic interventions have enhanced the management of these disorders, emphasizing the importance of early detection and personalized treatment strategies. Ongoing research continues to shed light on the underlying mechanisms of these diseases, paving the way for innovative therapies that aim to improve patient quality of life and reduce disease burden.

Understanding the Non-malignant Hematology Clinical Trial Landscape  

To get a better idea of what Non-malignant Hematology research looks like, we will use Citeline, a clinical trial intelligence platform, to outline what the Non-malignant Hematology clinical trial landscape looks like today.

Non-malignant Hematology Trials by Status  

To date, there have been over 21,500 Non-malignant Hematology trials. Just under 1700 are open and almost 1400 are planned. Here is a breakdown by status. 

Non-malignant Hematology Trials by Status 

Citeline Trialtrove® – 25NOV2024 

Trials by Phase

Non-malignant Hematology trials span all phases of development, with a significant number of Phase 4 trials. The reason for this is the nature of indications within this therapeutic area. Non-malignant hematologic disorders often require a longer period to understand safety and efficacy—more so than many other areas of medicine. Phase 4 trials allow researchers to better examine the long-term effects of treatment, analyze the impact on different subgroups, and leverage real world data over time.

Non-malignant Hematology Trials by Phase 

Citeline Trialtrove® – 25NOV2024

Non-malignant Hematology Trials by Start Date 

Let’s also look at Non-malignant Hematology trials by their start date. Overall, interest in this area of research has climbed modestly, but steadily over the last 10 years.6

Non-malignant Hematology Trials by Start Date, 2014-2024 

Citeline Trialtrove® – 25NOV2024 

Non-malignant Hematology Trials by Country   

Looking at planned and ongoing Non-malignant Hematology trials by site location is also interesting. Here are the top ten site locations for this research today.

Top 10 Non-malignant Hematology Trials by Site Country, 

 Chart Caption: Citeline Trialtrove® – 25NOV2024 

Precision's Expertise in Non-malignant Hematology Research           

At Precision for Medicine, we have worked on 17 Non-malignant Hematology trials.

Trials by Phase            

While the Non-malignant Hematology industry emphasizes Phase 4 clinical trials, our experience is more balanced.

Precision for Medicine's Non-malignant Hematology Trials by Phase 

Chart Caption: Citeline Trialtrove® – 25NOV2024 

Precision's Reach in Non-malignant Hematology Research  

Precision has extensive geographical experience working with sites globally where Non-malignant Hematology research is happening. 

Precision's Non-malignant Hematology Trials by Site Country 

Chart Caption: Citeline Trialtrove® – 25NOV2024 

The Precision Difference

Precision for Medicine is dedicated to advancing the understanding and treatment of non-malignant blood disorders. Our expertise spans the complexities of these conditions, from conducting comprehensive clinical trials to developing targeted therapeutic strategies. By leveraging our deep knowledge of hematology and commitment to patient-centered research, we strive to improve outcomes for individuals affected by these disorders.

Collaborating with healthcare providers and researchers worldwide, we aim to transform the landscape of non-malignant hematology, offering hope and improved quality of life to patients globally.